Evidence map›Paper›PMID 40921024›Full record

ArticleNeurology2025

Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies.

Jennifer L McGuire, Soniya Pinto, Esin Nur Erdogan, Yimei Li, Aashim Bhatia, Murat Alp Oztek, Arastoo Vossough, Jason N Wright, Ritu Shah, Naomi Torres Carapia and 15 more

Abstract readMulticenter Study
In one paragraph

Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Imaging the efficacy and side effects of CAR T-cell therapy in children and young adults.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Jennifer L McGuireChildren's Hospital of Philadelphia, PA.ORCID 0000-0002-8245-7199
Soniya PintoSt. Jude Children's Research Hospital, Memphis, TN.
Esin Nur ErdoganNorcliffe Foundation Center for Integrative Brain Research, Seattle Children's Research Institute, WA.
Yimei LiChildren's Hospital of Philadelphia, PA.
Aashim BhatiaChildren's Hospital of Philadelphia, PA.
Murat Alp OztekSeattle Children's, WA.
Arastoo VossoughChildren's Hospital of Philadelphia, PA.ORCID 0000-0003-1346-427X
Jason N WrightSeattle Children's, WA.
Ritu ShahNational Cancer Institute, Bethesda, MD.
Naomi Torres CarapiaChildren's Hospital Los Angeles, CA.
Nour ShamsUniversity of Tennessee, Knoxville.
Carly WestermannQuinnipiac University, North Haven, CT.
Agne TaraseviciuteChildren's Hospital Los Angeles, CA.
Bonnie YatesNational Cancer Institute, Bethesda, MD.
Swati NaikSt. Jude Children's Research Hospital, Memphis, TN.
Rebecca GardnerSt. Jude Children's Research Hospital, Memphis, TN.
Colleen AnnesleySeattle Children's, WA.
Emily HsiehChildren's Hospital Los Angeles, CA.
Caroline DiorioChildren's Hospital of Philadelphia, PA.
Regina MyersChildren's Hospital of Philadelphia, PA.
Rebecca EpperlySt. Jude Children's Research Hospital, Memphis, TN.
Aimee TalleurSt. Jude Children's Research Hospital, Memphis, TN.
Haneen ShalabiNational Cancer Institute, Bethesda, MD.
Nirali ShahNational Cancer Institute, Bethesda, MD.ORCID 0000-0002-8474-9080
Juliane GustNorcliffe Foundation Center for Integrative Brain Research, Seattle Children's Research Institute, WA.ORCID 0000-0001-5679-1989

Funding

USC/CHLA Summer Oncology Research Fellowship (SORF) Program for Medical StudentsR25CA225513 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI ANAT ERDREICH-EPSTEIN, WIJBE MARTIN KAST · 2019 to 2026
$1.7M
Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapyK08CA277013 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI Regina M Myers · 2023 to 2026
$721k
NCI NIH HHS K08 CA277013NCI NIH HHS R25 CA225513
6 · The paper itself

Abstract

BACKGROUND AND

objectivesNeuroimaging findings in immune effector cell-associated neurotoxicity syndrome (ICANS) have not been systematically described. We created the chimeric antigen receptor (CAR) T-cell Neurotoxicity Imaging Virtual Archive Library (CARNIVAL), a centralized imaging database for children and young adults receiving CAR T-cell therapy. Objectives of this study were to (1) characterize neuroimaging findings associated with ICANS and (2) determine whether specific ICANS-related neuroimaging findings are associated with individual neurologic symptoms.

methodsWe performed a multicenter retrospective cohort study of patients ≤30 years who experienced ICANS following CAR T-cell therapy for B-cell malignancies between January 1, 12, and January 31, 23, and had a brain MRI in the first 30 days after CAR T-cell infusion. Deidentified MRIs were reviewed by a central study team of pediatric neuroradiologists with experience in ICANS neuroimaging. Imaging features were categorized and correlated with CAR product and clinical characteristics including preinfusion neurologic history, and postinfusion neurologic symptoms alongside CAR T-cell toxicities using logistic regression.

resultsOf 864 patients treated with CD19 and/or CD22-directed CAR T-cells, 343 developed ICANS. 96 of the patients with ICANS (median age 12, 43% female) had an acute brain MRI. Of these, 36% (95% CI 27%-47%) had ICANS-related MRI abnormalities, most commonly affecting the white matter (24/35, 69%), brainstem (14/35, 40%), leptomeninges (10/35, 29%), and thalami (9/35, 26%). ICANS-related white matter abnormalities were generally bilateral, symmetric, and involved the supratentorial deep white structures, including the external and extreme capsules, corticospinal tracts, centrum semiovale, and periatrial white matter. There were no significant associations between ICANS-related MRI abnormalities and baseline clinical/demographic characteristic or specific ICANS symptoms, but higher ICANS grade was positively associated with MRI abnormalities (adjusted odds ratio 3.7, DISCUSSION: ICANS-related brain MRI abnormalities demonstrate unique patterns in the cerebral white matter, brainstem and thalami; their prevalence increases with ICANS clinical grade. Because our cohort is enriched for patients with severe ICANS, it likely overestimates the incidence of ICANS-related imaging abnormalities. A better understanding of neuroimaging findings is valuable for parsing pathophysiologic mechanisms of ICANS and optimizing patient outcomes.

Indexed as

BrainImmunotherapy, AdoptiveNeurotoxicity SyndromesAdolescentAdultChildChild, PreschoolCohort StudiesFemaleHumansInfantMagnetic Resonance ImagingMaleNeuroimagingRetrospective StudiesYoung Adult

Identifiers

PMID40921024
PMCPMC12442811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.